Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Should all patients at high risk of atherothrombotic events receive dual antiplatelet therapy?

Nature Clinical Practice Neurology volume 2, pages 532–533 (2006)Cite this article

Access through your institution
Buy or subscribe

boxed-textBhatt DL et al. for the CHARISMA Investigators (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354: 1706–1717

Background

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Diener HC et al. (2004) Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364: 331–337

    Article  CAS  Google Scholar 

  2. CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329–1339

  3. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345: 494–502

  4. Sabatine MS et al. (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352: 1179–1189

    Article  CAS  Google Scholar 

  5. Smith SC Jr et al. (2006) AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113: 2363–2372

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Hannah Camm, Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Presidential Distinguished Chair and Regents Professor of Neurology, and Co-director of the Cerebrovascular Section of the Department of Neurology, the Medical College of Georgia in Augusta, GA, USA

    Robert J Adams

Authors
  1. Robert J Adams
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Robert J Adams.

Ethics declarations

Competing interests

Robert Adams has given lectures sponsored by Boehringer Ingelheim, Bristol-Myers Squibb, Novartis and Sanofi-Aventis. He is on advisory committees in the area of stroke for Boehringer Ingelheim, Bristol-Myers Squibb and Sanofi-Aventis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Adams, R. Should all patients at high risk of atherothrombotic events receive dual antiplatelet therapy?. Nat Rev Neurol 2, 532–533 (2006). https://doi.org/10.1038/ncpneuro0297

Download citation

  • Received:

  • Accepted:

  • Issue date:

  • DOI: https://doi.org/10.1038/ncpneuro0297

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing